Peters S, Cho BC, Luft AV, Alatorre-Alexander J, et al. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial. J Thorac Oncol 2025;20:76-93.
PMID: 39243945